Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02449135
Expanded Access Status : Available
First Posted : May 20, 2015
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
Fuda Cancer Hospital, Guangzhou

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography(DSA) for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

Condition or disease Intervention/treatment
Pancreatic Cancer Procedure: interventional therapy

Detailed Description:
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography(DSA)for pancreatic cancer.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
Official Title: Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma:Clinical Trial



Intervention Details:
  • Procedure: interventional therapy
    Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography(DSA).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age:18-80
  2. Karnofsky performance status >60
  3. Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures.
  4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
  5. Will receive interventional therapy
  6. Life expectancy: Greater than 3 months
  7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities
  8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

  1. Patients with other primary tumor except pancreatic cancer
  2. History of coagulation disorders or anemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02449135


Contacts
Layout table for location contacts
Contact: Yuan Li, Master +86-15521338517 liyuan.lily@163.com
Contact: Xianghao Piao, PhD +86-18922210320 spacepiao@163.com

Locations
Layout table for location information
China, Guangdong
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China, 510000
Contact: Jibing Chen, PhD    +86-18903068207    jibingchen398@163.com   
Sponsors and Collaborators
Fuda Cancer Hospital, Guangzhou
Investigators
Layout table for investigator information
Study Chair: Lizhi Niu, PhD Fuda Cancer Hospital

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Fuda Cancer Hospital, Guangzhou
ClinicalTrials.gov Identifier: NCT02449135     History of Changes
Other Study ID Numbers: Nano drug pancreatic cancer
First Posted: May 20, 2015    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Keywords provided by Fuda Cancer Hospital, Guangzhou:
Pancreatic Cancer
Nano drug
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases